Pharma BD Deal Intelligence
Expensive acquisition loaded Schering-Plough with debt making it a Merck takeover target
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Schering-Plough completed its $14.43 billion acquisition of Organon BioSciences from Akzo Nobel, combining portfolios to strengthen human and animal health…
Schering-Plough acquired Organon for $14.5B.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Schering-Plough Corporation acquired Organon BioSciences N.V. from Akzo Nobel for approximately $14.4 billion (EUR 11 billion) in cash, gaining a pharmaceutical business (Organon) with $3.4 billion in 2006 sales, an animal health business (Intervet), and late-stage pipeline assets in women's health and CNS.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Schering-Plough Corp. / Organon International (this deal) | 2007 | $14.4B | 56 |
| Schering-Plough Corp. / Organon & Co. | 2007 | $14.4B | 48 |
| Schering-Plough Corp. / Organon BioSciences N.V. (Akzo Nobel) | 2007 | $14.5B | 48 |
| Schering-Plough Corp. / NeoGenesis Pharmaceuticals | 2005 | — | 30 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2007 deals · Schering-Plough Corp. deals · Neurology deals